Related Experiment Videos
T-cell specific immunosuppression by prodigiosin isolated from Serratia marcescens
1Korea Research Institute of Bioscience and Biotechnology (KRIBB), Yusung, Taejon, Republic of Korea.
International Journal of Immunopharmacology
|August 26, 1998
Summary
Prodigiosin, isolated from Serratia marcescens, selectively suppresses T-cell immune responses without harming B-cells. This immunosuppressant shows potential for clinical and immunological applications.
Area of Science:
- Immunology
- Microbiology
- Pharmacology
Background:
- Prodigiosin is a secondary metabolite produced by Serratia marcescens.
- Immunosuppressants are crucial for managing autoimmune diseases and preventing transplant rejection.
Purpose of the Study:
- To investigate the immunomodulatory effects of prodigiosin.
- To determine the specificity of prodigiosin's immunosuppressive activity on T-cells versus B-cells.
Main Methods:
- Prodigiosin was isolated from Serratia marcescens B-1231 culture broth.
- In vitro assays assessed T-cell proliferation (concanavalin-A), mixed lymphocyte response, and antibody production.
- In vivo toxicity studies evaluated lymphoid organ health at specified dosages.
Main Results:
- Prodigiosin effectively inhibited T-cell mediated immune responses at non-toxic concentrations.
- B-cell mediated immune functions remained unaffected by prodigiosin.
- No significant in vitro or in vivo toxicity was observed at effective concentrations/dosages.
Conclusions:
- Prodigiosin exhibits selective immunosuppressive activity, primarily targeting T-cells.
- Its non-toxic profile and potency comparable to existing immunosuppressants suggest therapeutic potential.
- Prodigiosin may serve as a valuable agent in clinical and immunological research and applications.